Lifeline Biotechnologies files patent for new breast cancer diagnostic system

As previously announced, Lifeline has been working diligently with a prominent Asian university to further develop and enhance the company’s First Warning System. This patent application is said to be the result of that extensive work.

Louis Keith, emeritus professor of obstetrics and gynecology at the Feinberg School of Medicine at Northwestern University, said: “We can now determine which of the thermal aberrations the First Warning System detects is similar to those associated with known cancers. Using a combination of five neural network constructions, we have broken this illusive barrier.

“This new system has the ability to provide us with 100% selectivity, finding all areas in the breast which generate abnormal thermal signals and, with specificity in the low nineties, correctly classifying them in terms of their similarity to signals obtained from patients with known cancers. This system will continue to improve in its accuracy over time because it learns from each new case presented to it.”

Jim Holmes, Lifeline’s CEO, said: “This effort represents extensive collaboration between Lifeline Biotechnology and two university professors who are renowned experts in thermal analysis and biotechnology. The new system utilizes five different types of neural network in tandem, a technique which has never been used to untangle the thermal information collected by the First Warning System.

“Now that we have filed this patent application with the US Patent and Trademark Office, we have begun the search for a strategic partner in earnest. We believe that a strategic partner will be better able to establish the First Warning System in the marketplace.”